Maria T. Stranieri

Medicine · Health Sciences

19h-index1.1kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(16), Antiplatelet Therapy and Cardiovascular Diseases(12), Heparin-Induced Thrombocytopenia and Thrombosis(7), Peptidase Inhibition and Analysis(5), Chemical synthesis and pharmacological studies(5)

Publications39 total

Crystal structure of thrombin in complex with compound 1
2004
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. implementation of P3 pyridine N-Oxides to deliver an orally bioavailable series containing P1 N-Benzylamides
Bioorganic & Medicinal Chemistry Letters·2003· 38 citedOpen Access
Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
Journal of Medicinal Chemistry·2003· 120 citedOpen Access
Thrombin-Hirugen-L405,426
2002
Crystal Structure of Thrombin in Complex with L-378,622
2002
Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation
Journal of Medicinal Chemistry·1999· 2 cited
Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation
Journal of Medicinal Chemistry·1999· 50 citedOpen Access
Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
Journal of Medicinal Chemistry·1998· 85 citedOpen Access
Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position
Journal of Medicinal Chemistry·1998· 105 citedOpen Access
C6 Modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption
Bioorganic & Medicinal Chemistry Letters·1998· 24 citedOpen Access
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
Bioorganic & Medicinal Chemistry Letters·1998· 69 citedOpen Access
Discovery and Development of the Novel Potent Orally Active Thrombin Inhibitor <i>N</i>-(9-Hydroxy-9-fluorenecarboxy)prolyl <i>trans</i>-4-Aminocyclohexylmethyl Amide (L-372,460):  Coapplication of Structure-Based Design and Rapid Multiple Analogue Synthesis on Solid Support
Journal of Medicinal Chemistry·1998· 78 citedOpen Access
Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734 217, in dogs
Biopharmaceutics & Drug Disposition·1997· 3 cited
ChemInform Abstract: Nonpeptide Glycoprotein IIb/IIIa Inhibitors. Part 13. Design and Synthesis of an Orally Active Pyrazolopiperazinone Nonpeptide Fibrinogen Receptor Antagonist.
ChemInform·1997
ChemInform Abstract: Nonpeptide GPIIb/IIIa Inhibitors. Part 16. Thieno(2,3‐b)thiophene . alpha.‐Sulfonamides are Potent Inhibitors of Platelet Aggregation.
ChemInform·1997
Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists
Journal of Medicinal Chemistry·1997· 56 citedOpen Access
Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist
Bioorganic & Medicinal Chemistry Letters·1997· 26 cited
Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic Efficacy of L-738,167, a Long-Acting GPIIb/IIIa Antagonist, Correlates with Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation but not with Bleeding Time Prolongation
Journal of Pharmacology and Experimental Therapeutics·1997· 14 cited
ChemInform Abstract: Nonpeptide GPIIB/IIIA Inhibitors. Part 10. Centrally Constrained alpha‐ Sulfonamides are Potent Inhibitors of Platelet Aggregation.
ChemInform·1997
ChemInform Abstract: Non‐Peptide Glycoprotein IIb/IIIa Antagonists. Part 11. Design and in vivo Evaluation of 3,4‐Dihydro‐1(1H)‐isoquinolinone‐Based Antagonists and Ethyl Ester Prodrugs.
ChemInform·1997· 1 cited
page 1 of 2Next →

Frequent Co-authors

Jacquelynn J. Cook(26), Joseph J. Lynch(26), Marie A. Holahan(25), Gary R. Sitko(21), Robert J. Lynch(15), George D. Hartman(14), Sidney D. Lewis(9), R J Gould(9), Bobby J. Lucas(8), Julie A. Krueger(8), Joseph P. Vacca(8), Robert J. Gould(8), Elizabeth A. Lyle(7), Rodney A. Bednar(7), Bohumil Bednář(7), Stanley L. Gaul(7), Jules A. Shafer(6), Adel M. Naylor-Olsen(6), Terry A. Lyle(5), Philip E.J. Sanderson(5)